Drug intelligence / Profile preview

DBT-03

Development stage: Preclinical
Lead developer: Discovery Biotech

Overview

DBT-03 is a preclinical-stage drug candidate being developed by Discovery Biotech to combat therapy resistance in cancer. The drug is part of a pipeline designed to address resistance mechanisms such as genetic mutations, alterations in drug processing, or changes in the tumor microenvironment. As of early 2024, Discovery Biotech has not publicly disclosed the specific molecular target, modality (e.g., small molecule or biologic), or the specific cancer types for which DBT-03 is being optimized.

Beyond the preview

Go deeper on DBT-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBT-03.

Explore the full profile